Top Markets
Coin of the day
TaiGen Biopharmaceuticals Holdings Limited TaiGen Biopharmaceuticals Holdings Limited

TaiGen Biopharmaceuticals Holdings Limited

4157
Classifica tra le azioni #18388
TaiGen Biopharmaceuticals Holdings Limited is a global pharmaceutical firm... TaiGen Biopharmaceuticals Holdings Limited is a global pharmaceutical firm dedicated to pioneering innovative treatments for life-altering diseases. Its robust development pipeline features several key assets. Among these is Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic currently being advanced for the treatment of various bacterial infections, including community-acquired pneumonia and diabetic foot infections. The company is also progressing Burixafor, a stem cell mobilizer with applications in stem cell transplantation and chemosensitization. Further contributing to its portfolio is TG-1000, an antiviral medication designed to combat influenza A, B, and the avian influenza H7N9 strain. Additionally, Furaprevir, a hepatitis C virus (HCV) protease inhibitor, is under development for managing chronic hepatitis C. Established in 2001, TaiGen Biopharmaceuticals maintains its headquarters in Taipei City, Taiwan.
Prezzo delle azioni
$0.28078542
Capitalizzazione di mercato
$199.87M
Variazione (1 giorno)
-0.34%
Variazione (1 anno)
-10.19%
Paese
TW
Scambia TaiGen Biopharmaceuticals Holdings Limited (4157)

Categoria

Rapporto P/S per TaiGen Biopharmaceuticals Holdings Limited (4157)
Rapporto P/S al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di TaiGen Biopharmaceuticals Holdings Limited, il rapporto P/S attuale (TTM) è 0. Alla fine del 2026, era pari a 0.
Storico del rapporto P/S per TaiGen Biopharmaceuticals Holdings Limited da 2026 a 2026
Rapporto P/S alla fine di ogni anno
Anno Rapporto P/S Cambia
Non abbastanza dati per le date fornite.
Rapporto P/S per aziende simili o concorrenti
Azienda Rapporto P/S Differenza del rapporto P/S Il paese
10.95 -
US
12.19 -
NL
24.99 -
US
3.75 -
AU
- -
CH